Trilogy International Partners Inc T.TRL.WT.A

Q2 results

[Chucklee]

TORONTO, ONTARIO, Jul 30, 2014 (Marketwired via COMTEX) -- Trimel Pharmaceuticals Corporation CA:TRL +3.39% today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014. Corporate Highlights Natesto(TM) Approval On May 28, 2014, the United States Food and Drug Administration approved Natesto(TM) (testosterone nasal gel), for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Tefina(TM) Phase II Results Also on May 28, 2014, Trimel announced positive top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina(TM), a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder ("FOD"). Women treated with Tefina(TM) 0.6 mg reported a 35% increase in the average number of orgasms versus placebo (p=0.0013) and 58% of women had at least one orgasm, compared to 43% of women in the placebo group. Tefina(TM) 0.6 mg also showed a statistically significant (p=0.017) improvement in distress over placebo. Estrace(R) Acquisition On July 16, 2014, the Company announced that it has acquired from Shire plc the Canadian rights for Estrace(R) (17-beta estradiol), a product indicated for the treatment of symptomatic relief of menopausal symptoms. Estrace(R) has been available on the Canadian market for 39 years and generated revenues of USD$9.9 million in 2013 within a hormone replacement therapy ("HRT") market valued at USD$100 million and grew by 6% in 2013. It is anticipated that Estrace(R) will contribute significantly to the Company's earnings before interest, tax, depreciation, and amortization ("EBITDA") and future cash flows. Source:https://www.marketwatch.com/story/trimel-provides-corporate-update-and-second-quarter-2014-financial-results-2014-07-30-18173415